1
|
Choi S and Myers JN: Molecular
pathogenesis of oral squamous cell carcinoma: implications for
therapy. J Dent Res. 87:14–32. 2008. View Article : Google Scholar
|
2
|
Gibson MK and Forastiere AA:
Multidisciplinary approaches in the management of advanced head and
neck tumors: state of the art. Curr Opin Oncol. 16:220–224. 2004.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Sasahira T, Kirita T and Kuniyasu H:
Update of molecular pathobiology in oral cancer: a review. Int J
Clin Oncol. 19:431–436. 2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Bushati N and Cohen SM: microRNA
functions. Annu Rev Cell Dev Biol. 23:175–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
6
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
7
|
Kluiver J, van den Berg A, de Jong D,
Blokzijl T, Harms G, Bouwman E, Jacobs S, Poppema S and Kroesen BJ:
Regulation of pri-microRNA BIC transcription and processing in
Burkitt lymphoma. Oncogene. 26:3769–3776. 2007. View Article : Google Scholar
|
8
|
Heegaard NH, Schetter AJ, Welsh JA, Yoneda
M, Bowman ED and Harris CC: Circulating micro-RNA expression
profiles in early stage nonsmall cell lung cancer. Int J Cancer.
130:1378–1386. 2012. View Article : Google Scholar :
|
9
|
Zhao XD, Zhang W, Liang HJ and Ji WY:
Overexpression of miR-155 promotes proliferation and invasion of
human laryngeal squamous cell carcinoma via targeting SOCS1 and
STAT3. PLoS One. 8:e563952013. View Article : Google Scholar
|
10
|
Bakirtzi K, Hatziapostolou M,
Karagiannides I, Polytarchou C, Jaeger S, Iliopoulos D and
Pothoulakis C: Neurotensin signaling activates microRNAs-21 and
-155 and Akt, promotes tumor growth in mice, and is increased in
human colon tumors. Gastroenterology. 141:1749–61.e1. 2011.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Yan XL, Jia YL, Chen L, Zeng Q, Zhou JN,
Fu CJ, Chen HX, Yuan HF, Li ZW, Shi L, et al: Hepatocellular
carcinoma-associated mesenchymal stem cells promote hepatocarcinoma
progression: role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology.
57:2274–2286. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Gironella M, Seux M, Xie MJ, Cano C,
Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, et
al: Tumor protein 53-induced nuclear protein 1 expression is
repressed by miR-155, and its restoration inhibits pancreatic tumor
development. Proc Natl Acad Sci USA. 104:16170–16175. 2007.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Zhang CM, Zhao J and Deng HY: MiR-155
promotes proliferation of human breast cancer MCF-7 cells through
targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci.
20:79–88. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Ling N, Gu J, Lei Z, Li M, Zhao J, Zhang
HT and Li X: microRNA-155 regulates cell proliferation and invasion
by targeting FOXO3a in glioma. Oncol Rep. 30:2111–2118.
2013.PubMed/NCBI
|
15
|
Zhang GJ, Xiao HX, Tian HP, Liu ZL, Xia SS
and Zhou T: Upregulation of microRNA-155 promotes the migration and
invasion of colorectal cancer cells through the regulation of
claudin-1 expression. Int J Mol Med. 31:1375–1380. 2013.PubMed/NCBI
|
16
|
Rather MI, Nagashri MN, Swamy SS, Gopinath
KS and Kumar A: Oncogenic microRNA-155 down-regulates tumor
suppressor CDC73 and promotes oral squamous cell carcinoma cell
proliferation: implications for cancer therapeutics. J Biol Chem.
288:608–618. 2013. View Article : Google Scholar :
|
17
|
Nazari-Jahantigh M, Wei Y, Noels H, Akhtar
S, Zhou Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, et
al: MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in
macrophages. J Clin Invest. 122:4190–4202. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Dent AL, Vasanwala FH and Toney LM:
Regulation of gene expression by the proto-oncogene BCL-6. Crit Rev
Oncol Hematol. 41:1–9. 2002. View Article : Google Scholar : PubMed/NCBI
|
19
|
Liu SC, Bassi DE, Zhang SY, Holoran D,
Conti CJ and Klein-Szanto AJ: Overexpression of cyclin D2 is
associated with increased in vivo invasiveness of human squamous
carcinoma cells. Mol Carcinog. 34:131–139. 2002. View Article : Google Scholar : PubMed/NCBI
|
20
|
Fernández de Mattos S, Essafi A, Soeiro I,
Pietersen AM, Birkenkamp KU, Edwards CS, Martino A, Nelson BH,
Francis JM, Jones MC, et al: FoxO3a and BCR-ABL regulate cyclin D2
transcription through a STAT5/BCL6-dependent mechanism. Mol Cell
Biol. 24:10058–10071. 2004. View Article : Google Scholar : PubMed/NCBI
|
21
|
Hirata Y, Ogasawara N, Sasaki M, Mizushima
T, Shimura T, Mizoshita T, Mori Y, Kubota E, Wada T, Tanida S, et
al: BCL6 degradation caused by the interaction with the C-terminus
of pro-HB-EGF induces cyclin D2 expression in gastric cancers. Br J
Cancer. 100:1320–1329. 2009. View Article : Google Scholar : PubMed/NCBI
|
22
|
Glauser DA and Schlegel W: The
FoxO/Bcl-6/cyclin D2 pathway mediates metabolic and growth factor
stimulation of proliferation in Min6 pancreatic beta-cells. J
Recept Signal Transduct Res. 29:293–298. 2009. View Article : Google Scholar : PubMed/NCBI
|
23
|
Lao G, Liu P, Wu Q, Zhang W, Liu Y, Yang L
and Ma C: Mir-155 promotes cervical cancer cell proliferation
through suppression of its target gene LKB1. Tumour Biol.
35:11933–11938. 2014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Shi LJ, Zhang CY, Zhou ZT, Ma JY, Liu Y,
Bao ZX and Jiang WW: MicroRNA-155 in oral squamous cell carcinoma:
Overexpression, localization, and prognostic potential. Head Neck.
37:970–976. 2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Gombos K, Horváth R, Szele E, Juhász K,
Gocze K, Somlai K, Pajkos G, Ember I and Olasz L: miRNA expression
profiles of oral squamous cell carcinomas. Anticancer Res.
33:1511–1517. 2013.PubMed/NCBI
|
26
|
Johansson J, Berg T, Kurzejamska E, Pang
MF, Tabor V, Jansson M, Roswall P, Pietras K, Sund M, Religa P and
Fuxe J: MiR-155-mediated loss of C/EBPβ shifts the TGF-β response
from growth inhibition to epithelial-mesenchymal transition,
invasion and metastasis in breast cancer. Oncogene. 32:5614–5624.
2013. View Article : Google Scholar : PubMed/NCBI
|
27
|
Sandhu SK, Volinia S, Costinean S, Galasso
M, Neinast R, Santhanam R, Parthun MR, Perrotti D, Marcucci G,
Garzon R and Croce CM: miR-155 targets histone deacetylase 4
(HDAC4) and impairs transcriptional activity of B-cell lymphoma 6
(BCL6) in the Eμ-miR-155 transgenic mouse model. Proc Natl Acad Sci
USA. 109:20047–20052. 2012. View Article : Google Scholar
|
28
|
Ponzio G, Loubat A, Rochet N, Turchi L,
Rezzonico R, Farahi Far D, Dulic V and Rossi B: Early G1 growth
arrest of hybridoma B cells by DMSO involves cyclin D2 inhibition
and p21(CIP1) induction. Oncogene. 17:1159–1166. 1998. View Article : Google Scholar : PubMed/NCBI
|
29
|
Shaffer AL, Yu X, He Y, Boldrick J, Chan
EP and Staudt LM: BCL-6 represses genes that function in lymphocyte
differentiation, inflammation, and cell cycle control. Immunity.
13:199–212. 2000. View Article : Google Scholar : PubMed/NCBI
|